Add Formweb to your mobile device
Search results for:
octreotide
octreotide
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| SandoSTATIN LAR Depot | POWDER FOR INJECTION, INTRAMUSCULAR | 10 mg | |
| SandoSTATIN LAR Depot | POWDER FOR INJECTION, INTRAMUSCULAR | 20 mg | |
| SandoSTATIN LAR Depot | POWDER FOR INJECTION, INTRAMUSCULAR | 30 mg | |
| Octreotide Acetate | SOLUTION, INJECTABLE | 50 mcg/mL | |
| Octreotide Acetate | SOLUTION, INJECTABLE | 100 mcg/mL | |
| Octreotide Acetate | SOLUTION, INJECTABLE | 200 mcg/mL | |
| Octreotide Acetate | SOLUTION, INJECTABLE | 500 mcg/mL | |
| Octreotide Acetate | SOLUTION, INJECTABLE | 1000 mcg/mL |
Last updated: Jan. 9, 2024
Solution for injection vials are labeled for SC administration but may be given IV (per manufacturer). Refer to medication order for specified route of administration.
The long acting (LAR) intramuscular injection is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.